Bronchitis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
Line 16: | Line 16: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Latest revision as of 20:44, 29 July 2020
Bronchitis Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]; Nate Michalak, B.A.
Overview
The most important step to decrease the comorbidities secondary to bronchitis is smoking cessation. For those who have occupational exposure to dusts or aerosols, transfer to a safer environment is helpful.
Secondary prevention
- Acute bronchitis: Smoking cessation will help to repair the bronchial tree damages and is an effective measure regarding secondary prevention.[1]
- Chronic bronchitis: Although chronic bronchitis is not curable, it can be controlled in a variety of ways. Clinical practice guidelines by Global Initiative for Chronic Obstructive Lung Disease (GOLD), a collaboration including the American National Heart, Lung, and Blood Institute and the World Health Organization, are available.[2]
- Smoking Cessation
- Smoking cessation is one of the most important factors in slowing down the progression of COPD. Even at a late stage of the disease, it can reduce the rate of deterioration and prolong the time taken for disability and death.
- Occupational Change
- Workers may be able to transfer to a significantly less contaminated area of the company depending on circumstances. However, workers may need complete occupational change.
References
- ↑ The American Academy of Family Physicians: Acute Bronchitis. January 2006. Accessed 20 March 2007
- ↑ Rabe KF, Hurd S, Anzueto A; et al. (2007). "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary". Am. J. Respir. Crit. Care Med. 176 (6): 532–55. doi:10.1164/rccm.200703-456SO. PMID 17507545.